Personalized treatment for early-stage breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have early-stage breast cancer (no spread to distant parts of the body).
- Your cancer must be HER2-positive or triple-negative (specific subtypes of breast cancer).
- You must be planning to get chemotherapy before surgery and radiation after.
- You cannot be pregnant or breastfeeding.
- You cannot have cancer that has spread to the skin or distant organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.